Hyperlipidemic conditions were shown to contribute to ROS production, breast cancer progression, and MAPK activation, whereas treatment with febuxostat, xanthine oxidase inhibitor, by diminishing ROS levels and AQP5 expression, mitigated proliferative and migratory ability of breast cancer cells, as well as pulmonary metastases [105]. Here, AQP5 is linked to breast cancer.